Nerandomilast Patent Expiration
Nerandomilast was first introduced by Boehringer Ingelheim Pharmaceuticals Inc
Nerandomilast Patents
Given below is the list of patents protecting Nerandomilast, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Jascayd | US11406638 | Combination Of Active Agents For The Treatment Of Progressive Fibrosing Interstitial Lung Diseases (Pf-Ild) | Oct 22, 2038 | Boehringer Ingelheim |
| Jascayd | US11813266 | Combination Of Active Agents For The Treatment Of Progressive Fibrosing Interstitial Lung Diseases (Pf-Ild) | Oct 22, 2038 | Boehringer Ingelheim |
| Jascayd | US9802954 | Piperidino-Dihydrothienopyrimidine Sulfoxides And Their Use For Treating Copd And Asthma | Feb 19, 2034 | Boehringer Ingelheim |
| Jascayd | US8609670 | Piperidino-Dihydrothienopyrimidine Sulfoxides And Their Use For Treating Copd And Asthma | Aug 23, 2032 | Boehringer Ingelheim |
| Jascayd | US8754073 | Substituted Piperazino-Dihydrothienopyrimidines | Nov 26, 2029 | Boehringer Ingelheim |
Nerandomilast's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Nerandomilast:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
